Kornimate/medical-research-clean huggingface dataset:
the reversal of neuromuscular adaptation in human with spinal cord injury ii

Conditions: Spinal Cord Injury(SCI)

Summary: following injury to the spinal cord, the spinal circuit undergoes a series of adaptations. in parallel with the spinal circuit adaptation, the muscular properties also adapt. in human and animal studies, histochemical and physiological evidences showed that the paralyzed muscle transferred from slow, fatigue-resistant to fast, fatigable after injury. reversal of neuromuscular property for persons with sci needs to be resolved. studies using high load electrical stimulations showed a reverse change of muscular properties, such as hypertrophy and reversal of fiber type transformations but failed to show a reversal of spinal circuitry function. previous studies found that fast continuous passive motion (cpm) altered the h reflex excitability in human. animal studies found that passive cycling and passive stretching delayed atrophy and influenced the transition of type i and iia mhc. theses findings lead to a hypothesis that mechanical stimulation might be able to reverse both spinal circuitry and muscular properties after sci but it has not been confirmed in human study. the purpose of this project is to investigate the effect of mechanical stimulation by fast cpm on the reversing adaptation of human paralyzed muscle after sci.


Eligibility criteria:
stage 1 subjects: spinal cord injury subject inclusion criteria: * clinical diagnosis of spinal cord injury \< 2 years stage 2 subjects: incomplete spinal cord injury subject inclusion criteria: * clinical diagnosis of incomplete spinal cord injury * asia classification:b, c, or d stage 3 subjects: spinal cord injury subjects with high muscle tone inclusion criteria: * clinical diagnosis of spinal cord injury. * asia classification: a, b, c, or d

Keywords: reflex post activation spinal cord injury pre-synaptic inhibition machine driven passive strech
observational study to evaluate bipolar disorder symptoms in patients presented with schizophrenia or depression

Conditions: Schizophrenia; Schizoaffective Disorder; Recurrent Depression

Summary: this study is aimed to evaluate the bipolar disorder symptoms in patients presented with schizophrenia, schizoaffective disorder or recurrent depression. bipolar disorder is a group of mood disorders characterised by elevated or irritable mood episodes in patient's lifetime history accompanied by some additional symptoms. in this study modern bipolar disorders screening/assessment instruments will be used to explore the prevalence of bipolarity symptoms in patients who never been diagnosed with bipolar disorders. the results of this study could be useful for more accurate assessment of bipolar disorders prevalence in psychiatric patient population, could help to improve the diagnostics of bipolar disorders and management of bipolar patients.


Eligibility criteria:
inclusion criteria: * signed patient informed consent * in-patients with the diagnosis of schizophrenia with episodic course or schizoaffective disorder, or in-patients and out-patients with the diagnosis of recurrent depression. * the duration of the disease is 3 years and longer and two or more episodes of the disease in the patients history. exclusion criteria: * current diagnosis of bipolar disorder * severe and unspecified forms of schizophrenia (schizophrenia with continuous course, hebephrenic schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, unspecified schizophrenia) and organic affective disorder or intoxication induced affective disorder. * any other concomitant conditions which, in the judgment of investigator, will not allow the patient to complete the study procedures

Keywords: schizophrenia schizoaffective disorder recurrent depression bipolar disorders
"information technology methodology for patient motivation in diabetes management."

Conditions: Type 2 Diabetes

Summary: type 2 diabetes is a chronic metabolic disorder requiring lifestyle modification and medicines, adherence to which has to be practised on a daily basis. motivation of patients to adhere to treatment is difficult in clinical practice. it is well documented that majority of patients do not reach the glycaemic targets even in the centres of excellence. regular short service messages (sms) through cell phones could have a positive effect on behaviour and adherence to life style changes and compliance to drugs. it may be practical and feasible to use information technology as an effective and simple tool for motivating patients to adhere to the prescribed treatment regimen. in diabetic patients, frequent reminders regarding the need for adherence to lsm and drugs by the medical professionals will improve the compliance.

in diabetic patients, frequent reminders by the medical professionals on the need for adherence to life style modification (lsm) and drugs will improve the compliance. sms may be an effective and cheap tool of communication. improved compliance is likely to result in better glycaemic control. out of total number of 200, consecutive randomization of 100 patients each to sms or usual care arms will be done. patients in the sms group will get sms once in 3 days as a reminder. patients will be reviewed at 3, 6, 9 and 12 months from the date of randomization fasting and 2hr postprandial glucose and hba1c will be tested during each visit. at baseline and at the end of the study, lipids, and renal function test will also be done. a validated questionnaire will be used to assess physical activity, diet habits, adherence to drug prescriptions and frequency of monitoring of blood glucose. . body weight, blood pressure, biochemical variables, scores for diet and physical activity and compliance to drugs, will be compared using students 't' test or chi-square test as relevant.

Eligibility criteria:
inclusion criteria: * male or female, 30-65 yrs of age at the time of entry and have type 2 diabetes for a minimum period of 5 years. * hba1c ranging 8.0-10.0% * patients either receiving oha and / or insulin exclusion criteria: * type 1 diabetes * patients with history of blindness, decreased vision * serious vascular complications : * cancer

Keywords: life style modification, type 2 diabetes, sms, patient adherence
the effect of pf-03654764 +/- allegra on symptoms of allergic rhinitis

Conditions: Allergic Rhinitis

Summary: pf-03654764 should reduce the symptoms of allergic rhinitis. in this study patients will be exposed to pollen and their symptoms observed.


Eligibility criteria:
inclusion criteria: * male or female subjects 18-60 years allergic to ragweed pollen. * subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit. exclusion criteria: * subjects with significant diseases other than allergic rhinitis that may interfere with the safety or efficacy of pf-03654764. * subjects with significant symptoms of allergic rhinitis within the 2 weeks prior to screening.

Keywords: allergic rhinitis environmental exposure unit
a fmri study of the treatment of danish veterans with ptsd with prolonged exposure therapy

Conditions: Stress Disorders, Post-Traumatic

Summary: in this article, the investigators report the design and protocol of a functional magnetic resonance imaging study (fmri) of the treatment of danish veterans with ptsd with prolonged exposure therapy (pe). in total 30 danish veterans will be recruited, who meet the icd-10 diagnostic criteria for ptsd, and treated with pe. a group of controls will be recruited consisting of age-appropriate same sex veterans who have participated in international missions similar to the patient group

primary outcome measures are the changes in d2-test assessment of attention and concentration, beck depression inventory, post-traumatic symptom scale-interview version and ptsd checklist- military version. secondary outcome measures concern changes of brain derived neurotrophic factor (bndf) and changes in the brain structure with focus on the hippocampal function using fmri.

Eligibility criteria:
inclusion criteria: * cases: danish veterans with icd-10 diagnostic criteria for ptsd * controls: danish veterans without icd-10 diagnostic criteria for ptsd exclusion criteria: * participants who have an active abuse of psychoactive substances with daily consumption. * participants who consume more than 21 units of alcohol per week, and who, during the last month, have had repetitive episodes with craving, episodes of loss of control due to alcohol consumption, and a weakened ability to manage consumption, stop or reduce consumption * participants who have a current icd-10 diagnosis within: * f20 to f29 schizophrenia * schizotypical mental disorder * delusional disorder * acute and transient psychotic disorders and schizoaffective psychosis * f30 manic single episode * f31 bipolar affective disorder * f60.2 dyssocial personality structure * f60.3 emotionally unstable personality structure * f90 hyperkinetic disorder (adhd) f98.8 other behavioural and emotional disorders in childhood and adolescence (add) * participants who have a daily intake of sedative, anxiolytic * participants who score below 23 on the mini mental state examination, and (5) * participants who within the last 3 months have had a serious suicide attempt. * exclusion criteria related to the fmri scanning include: * ferromagnetic prostheses (including straps prostheses, clips on blood vessels, pacemakers, and metal splinters) * claustrophobia and movements during the scan.
smoking relapse prevention via just-in-time-adaptive interventions

Conditions: Smoking Cessation

Summary: a small-scale randomized controlled trial (rct) will pilot test a personalized jitai designed to guide delivery of fast acting nicotine replacement therapy (nrt; lozenge) in real-time, to prevent smoking relapse. specifically, a smartphone application (app), will integrate pre-quit smoking data with objective location data captured via global positioning system (gps) to establish relapse risk (hotspot) algorithms. during a quit attempt, the gps-enabled app (quitbuddy) will detect proximity to hotspots and deliver nrt prompts, all of which will occur automatically and prior to exposure. thus, quitbuddy will optimize nrt use to prevent cue-provoked cravings known to undermine sustained abstinence, thereby repurposing this evidence-based cessation medication to promote relapse prevention. quitbuddy will be tested against standard care (nrt with brief instructions). two versions of quitbuddy will be tested, which will differ only in how hotspot algorithms are derived: retrospectively from locations recalled at the onset of a quit attempt (quitbuddy-recall) or based on real-time ema completed pre-quit (quitbuddy).


Eligibility criteria:
inclusion criteria: * at least 18 years of age * daily cigarette smoker of \> 9 cigarettes/day for past year * co breath monitor detects \> 10ppm * literate in english * willing to make a quit attempt in the next week with nicotine replacement therapy * no plans to travel outside of a 100-mile radius of charleston during the study exclusion criteria: * fda contraindications for use of nrt: 1. pregnant 2. breastfeeding or planning to become pregnant 3. recent (past 3 months) cardiovascular trauma: mi, stroke * current use (past 30 days) of alternative tobacco products or smoking cessation medications
study to assess safety and tolerability of azd0530 in combination with carboplatin and paclitaxel

Conditions: Cancer; Non Small Cell Lung Cancer; Epithelial Ovarian Cancer

Summary: the primary purpose of this study is to explore the safety and tolerability of azd0530 in combination with carboplatin and paclitaxel in japanese patients with non small cell lung cancer and epithelial ovarian cancer.


Eligibility criteria:
inclusion criteria: * japanese patients with non small cell lung cancer or epithelial ovarian cancer * must be suitable for treatment with carboplatin and paclitaxel * relatively good overall health other than cancer exclusion criteria: * poor bone marrow function (not producing enough blood cells). * poor liver or kidney function. * patients unable to discontinue drugs known to be potent inhibitors or inducers of cyp3a4 within 2 weeks prior to registration

Keywords: phase i cancer solid tumors advanced solid malignancies nsclc epithelial ovarian cancer dose escalation combination treatment src inhibitor japanese
development and efficacy evaluation of integrated chronic care and health promotion model for patients with coronary artery disease in taiwan

Conditions: Acute Myocardial Infarction; Stable Angina

Summary: the hypothesis of this project is to examine whether the integrated health care program as the intervention group can reduce the recurrence and mortality of coronary artery-related diseases than the traditional one as the comparison group.


Eligibility criteria:
inclusion criteria: * patients who suffered from acute myocardial infarction or stable angina with intervention (cabg or ptca) exclusion criteria: 1. age \> 85 yrs old. 2. worse short-term prognosis (e.g.cancer, congestive heart failure nyha iv) 3. any systemic disease which will limit the exercise program (e.g. bed-ridden stroke) 4. unable to participate in the trial due to any logic reasons

Keywords: intervention cabg or ptca
interleukin-2 in metastatic melanoma

Conditions: Melanoma Metastatic

Summary: to determine whether interleukin-2 at the dose and schedule will help to increase tumor shrinkage

in this phase ii trial, the previously described il-2 schedule (daily il-2 for 5 days (per week) every 3 weeks) will be tested in a larger cohort of patients with melanoma to attempt to determine the response rate, median duration of response, and median survival. the dose intensity of this schedule would allow a patient treated on this regimen to achieve the target threshold (\> 1440 million iu/m2/year).

Eligibility criteria:
inclusion criteria: 1. patients must have a histologic diagnosis of metastatic melanoma. patients may have received prior systemic therapy or may be previously untreated. 2. patients must have bi-dimensional measurable disease on physical exam or radiologic studies. 3. ecog performance status of 0 or 1 and estimated survival of at least 3 months. 4. white blood count of \> 3500/mm3, platelet count \> 100,000/mm3, hemoglobin \> 9.0 gm/dl; bilirubin, alt, ast \< 3 x upper limit of normal; serum creatinine \< 2.0 mg/dl. 5. patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. patients with a positive stress test would be excluded from this trial. 6. patients with elevated temperatures \> 100.5 f must have sources of occult infection excluded. 7. patients must be felt to have recovered from effects of prior therapy, such as \> 2 weeks after prior chemotherapy. 8. patient consent must be obtained prior to entrance onto study. 9. women of childbearing potential must have a negative pregnancy test and must take adequate precautions to prevent pregnancy during treatment exclusion criteria: 1. medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate. 2. autoimmune disease such as inflammatory arthritis which could be exacerbated by immune-based therapy. 3. prior history of psychiatric disorder which could be exacerbated by interleukin-2. 4. lactation or pregnancy. 5. evidence of significant cardiovascular disease including history of recent (\< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional pvc's, angina, positive low-level stress test, or cerebrovascular accident. 6. current brain metastasis.

Keywords: metastatic melanoma
til relation to pcr after neoadjuvant therapy in breast cancer patients

Conditions: Breast Cancer

Summary: neoadjuvant systemic treatment for breast cancer (used in locally advanced and operable breast cancer) includes anthracycline based chemotherapy (doxorubicin/cyclophosphamide) followed by taxanes (weekly paclitaxel or docetaxel) with antiher-2 trastuzumab or dual antiher-2 trastuzumab plus pertuzumab. other regimens include docetaxel plus carboplatin plus trastuzumab alone or combined with pertuzumab for her-2 positive patients. the tumor microenvironment, which includes extracellular matrix and stromal cells, is a key factor in tumorigenicity and the prediction of the efficacy of immunotherapy, conventional chemotherapy, and other anticancer therapies. tumor-infiltrating lymphocytes (tils), one of the most important components of the tumor microenvironment, were reported to predict the response to nac both for tumors and axillary lymph nodes in breast cancer patients. this study is conducted to examine the relationship between tumor-infiltrating lymphocytes (categorized into three levels) and the pathologic complete response to neoadjuvant systemic therapy in breast cancer patients, and to examine the relationship between tils and 1-year invasive disease-free survival (idfs).

neoadjuvant systemic treatment for breast cancer is used in locally advanced and operable breast cancer. standard neoadjuvant systemic therapy regimens for breast cancer patients include anthracycline based chemotherapy (doxorubicin/cyclophosphamide) followed by taxanes (weekly paclitaxel or docetaxel) with antiher-2 trastuzumab or dual antiher-2 trastuzumab plus pertuzumab. other regimens include docetaxel plus carboplatin plus trastuzumab alone or combined with pertuzumab for her-2 positive patients. the tumor microenvironment, which includes extracellular matrix and stromal cells, is a key factor in tumorigenicity and the prediction of the efficacy of immunotherapy, conventional chemotherapy, and other anticancer therapies. tumor-infiltrating lymphocytes (tils), one of the most important components of the tumor microenvironment, were reported to predict the response to nac both for tumors and axillary lymph nodes in breast cancer patients. this study is conducted to examine the relationship between tumor-infiltrating lymphocytes (categorized into three levels) and the pathologic complete response to neoadjuvant systemic therapy in breast cancer patients, and to examine the relationship between tils and 1-year invasive disease-free survival (idfs).

Eligibility criteria:
inclusion criteria: * patients aged 18 years old or more * histologically proven invasive breast cancer * all patients diagnosed with breast cancer except t1n0 and metastatic breast cancer * patients who completed their systemic neoadjuvant therapy exclusion criteria: * second malignancy * patients who started but didn't complete neoadjuvant systemic therapy * patients who didn't undergo surgery after neoadjuvant systemic therapy * pregnant patients

Keywords: tumor-infiltrating lymphocytes
efficacy and safety study of low dose oral contraceptive pill to treat primary dysmenorrhea

Conditions: Dysmenorrhea

Summary: the purpose of this study is to determine whether combination oral contraceptive pill of norethindrone and ethinyl estradiol is effective in the treatment of primary dysmenorrhea.


Eligibility criteria:
inclusion criteria: * primary dysmenorrhea exclusion criteria: * severe hepatopathy * pregnant woman
effectiveness of breg flex in 12-week peri-operative total knee arthroplasty

Conditions: Knee Osteoarthritis

Summary: patient outcomes following total knee replacement and standard physical therapy will be compared between subjects who use the breg flex study device vs those who do not. subjects will be evaluated for knee range of motion, strength and patient reported outcomes.


Eligibility criteria:
inclusion criteria: 1. individuals who are scheduled for total knee arthroplasty by a single surgeon (burnikel) 2. individuals who are at least 55 years of age 3. individuals with a body mass index (bmi) \<45 4. must be able and willing to complete all study assessments and to be followed for the full course of the study. 5. must be able to read, write and follow instructions in english. 6. must be able and willing to provide informed consent. 7. must be willing and able to attend the pre-op assessment exclusion criteria: 1. individuals with a history of any underlying neurological conditions 2. individuals with a history of stroke 3. individuals with a history of neurological disorder that affects lower extremity function (stroke, peripheral neuropathy, parkinson's disease, multiple sclerosis, etc.) 4. individuals with physical conditions which would make them unable to perform study procedures 5. pregnant women or inadequate precautions to prevent pregnancy 6. diagnosis of a medical condition that would contraindicate treatment with the product, e.g. skin lesions at electrode site. 7. individuals with a diagnosis of inflammatory arthritis (rheumatoid arthritis, gout or psoriatic arthritis)? 8. individuals with muscle diseases (i.e. muscular dystrophy) 9. visible skin injury or disease on their legs 10. principal investigator for this study, or member of study staff
europainclinics® study iv (prospective observational study)

Conditions: Low Back Pain; Facet Joint Pain

Summary: in this prospective observational trial the effect of the endoscopic rhizotomy microinvasive therapy should be examined in (approximately 150) adult patients with low back pain positive for facet joint pain component.

facet joint pain encompasses a significant portion of possible sources of pain in patients with vertebrogenic algic syndrome. a typical symptom is intermittent radiation of pain in the back and legs. the cause of this pain is irritation of the medial branch of the dorsal nerve root, which innervates a facet joint. confirmation of the source of pain involves using a local anaesthetic to block the medial branches of several vertebral areas. if, through this test, the facet joints are determined to be the source of pain the patient's condition is indicated for radiofrequency ablation of the nerve branches. europainclinics® study iv (epcs iv) is a prospective observational comparative study that will use pain scales to analyse changes in the neurological status of nerves of patients who undergo the minimally invasive procedure: radiofrequency nerve ablation and cryoablation of the lumber facet joints. the study aims to investigate documented clinical results of the neurological conditions of patients, to compare pain scales and the use of analgesics over a number of time periods: prior to the procedure, 6 weeks post-procedure, as well as 6 and 12 months post-procedure. the data will be subsequently statistically analysed.

Eligibility criteria:
inclusion criteria: * patients who undergo endoscopic rhizotomy therapy exclusion criteria: * no

Keywords: low back pain facet joints endoscopic rhizotomy
comparative study of rifaximin versus norfloxacin in the secondary prophylaxis of spontaneous bacterial peritonitis

Conditions: Spontaneous Bacterial Peritonitis; Ascites; Liver Cirrhosis

Summary: the aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for secondary prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.

this study will be carried out on 100 patients with liver cirrhosis and ascites who will be enrolled from tanta university, tropical medicine department in the period between january 2014 to 6 months. the selected patients will be randomly assigned to receive 400 mg of norfloxacin daily or 1200 mg of rifaximin daily and will be classified into two groups : group 1 : 50 patients will be treated with 1200 mg of rifaximin daily. group 2 : 50 patients will be treated with 400 mg of norfloxacin daily.

Eligibility criteria:
inclusion criteria: * previous episode of sbp * total protein in the ascitic fluid below or equal to 1.5 g/dl exclusion criteria: * allergy to quinolones * antibiotic therapy in the 2 weeks preceding inclusion * recent ( within the previous 2 weeks) episode of digestive hemorrhage * hepatocellular carcinoma or other neoplasias able to shorten life expectancy * pregnant and lactating women